{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:14:19Z","timestamp":1792880059579,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.jhep.2009.03.025","type":"journal-article","created":{"date-parts":[[2009,5,19]],"date-time":"2009-05-19T05:23:08Z","timestamp":1242710588000},"page":"380-388","source":"Crossref","is-referenced-by-count":265,"title":["Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis"],"prefix":"10.1016","volume":"51","author":[{"given":"Songwen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C.","family":"Harnish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2009.03.025_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.03.025_bib2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.03.025_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.03.025_bib4","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.03.025_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.03.025_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","article-title":"Association of nonalcoholic fatty liver disease with insulin resistance","volume":"107","author":"Marchesini","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2009.03.025_bib7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.03.025_bib8","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1053\/j.gastro.2008.02.077","article-title":"Diagnosis and therapy of nonalcoholic steatohepatitis","volume":"134","author":"Torres","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.03.025_bib9","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.03.025_bib10","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.03.025_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2009.03.025_bib12","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jhep.2009.03.025_bib13","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jhep.2009.03.025_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhep.2009.03.025_bib15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/med.1023","article-title":"Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism","volume":"21","author":"Willson","year":"2001","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jhep.2009.03.025_bib16","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhep.2009.03.025_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jhep.2009.03.025_bib18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2009.03.025_bib19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhep.2009.03.025_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhep.2009.03.025_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.febslet.2007.11.015","article-title":"FXR signaling in metabolic disease","volume":"582","author":"Zhang","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jhep.2009.03.025_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.amjcard.2007.08.008","article-title":"Liver X receptor and farnesoid X receptor as therapeutic targets","volume":"100","author":"Rader","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jhep.2009.03.025_bib23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2009.03.025_bib24","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","article-title":"Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice","volume":"28","author":"Kim","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jhep.2009.03.025_bib25","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1172\/JCI18945","article-title":"Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis","volume":"112","author":"Liu","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2009.03.025_bib26","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","article-title":"A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis","volume":"314","author":"Fiorucci","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2009.03.025_bib27","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.03.025_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1194\/jlr.M800323-JLR200","article-title":"Loss of small heterodimer partner (SHP) expression in the liver protects against dyslipidemia","volume":"50","author":"Hartman","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2009.03.025_bib29","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1161\/CIRCULATIONAHA.104.523563","article-title":"Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice","volume":"111","author":"Zhang","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2009.03.025_bib30","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2009.03.025_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1101\/gad.1138104","article-title":"Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR","volume":"18","author":"Zhang","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.jhep.2009.03.025_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.bbrc.2005.01.141","article-title":"Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor","volume":"329","author":"Savkur","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2009.03.025_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0959-9673.2006.00465.x","article-title":"Mouse models in non-alcoholic fatty liver disease and steatohepatitis research","volume":"87","author":"Anstee","year":"2006","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.jhep.2009.03.025_bib34","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1194\/jlr.M500390-JLR200","article-title":"Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice","volume":"46","author":"Hanniman","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2009.03.025_bib35","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1161\/01.ATV.0000235697.35431.05","article-title":"FXR deficiency causes reduced atherosclerosis in Ldlr-\/- mice","volume":"26","author":"Zhang","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2009.03.025_bib36","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/ATVBAHA.107.152694","article-title":"Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration","volume":"27","author":"Li","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2009.03.025_bib37","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bbalip.2006.09.018","article-title":"Effects of FXR in foam-cell formation and atherosclerosis development","volume":"1761","author":"Guo","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhep.2009.03.025_bib38","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1073\/pnas.0400046101","article-title":"Expression and activation of the farnesoid X receptor in the vasculature","volume":"101","author":"Bishop-Bailey","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2009.03.025_bib39","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2337\/db06-1642","article-title":"Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy","volume":"56","author":"Jiang","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2009.03.025_bib40","doi-asserted-by":"crossref","unstructured":"Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem 2009. [Epub ahead of print].","DOI":"10.1021\/jm8014124"},{"key":"10.1016\/j.jhep.2009.03.025_bib41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/jhep.2003.50316","article-title":"Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E","volume":"38","author":"Kugelmas","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.03.025_bib42","first-page":"1549","article-title":"Levels of serum hyaluronic acid, TNF-\u03b1 and IL-8 in patients with nonalcoholic steatohepatitis","volume":"52","author":"Bahcecioglu","year":"2005","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2009.03.025_bib43","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2006.02.011","article-title":"Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2","volume":"44","author":"Haukeland","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2009.03.025_bib44","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1016\/S0021-9258(19)84972-4","article-title":"The platelet-derived growth factor-inducible KC gene encodes a secretory protein related to platelet alpha-granule proteins","volume":"264","author":"Oquendo","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2009.03.025_bib45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.108.144600","article-title":"Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet","volume":"328","author":"Kong","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2009.03.025_bib46","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.bbrc.2008.12.117","article-title":"Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists","volume":"379","author":"Zhang","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2009.03.025_bib47","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882780900316X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882780900316X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T16:59:30Z","timestamp":1633453170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882780900316X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S016882780900316X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2009.03.025","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}